Trial Profile

The Combination of Pembrolizumab and Lenvatinib as Neoadjuvant Treatment for Hepatocellular Carcinoma Patients: a Single Arm Phase II Study

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 18 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenvatinib (Primary) ; Pembrolizumab (Primary)
Indications Carcinoma; Cholangiocarcinoma; Liver cancer
Focus Therapeutic Use
Acronyms NeoLeap-HCC

Most Recent Events

04 Jun 2024 Results (At the data cutoff (Dec 15, 2023), n=42) assessing safety and efficacy of Perioperative pembrolizumab and lenvatinib for resectable hepatocellular carcinoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology
20 Sep 2023 Status changed from recruiting to active, no longer recruiting.
17 Apr 2023 Planned End Date changed from 31 Jul 2025 to 1 Oct 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com